Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
Will Novo Nordisk (NVO) Stock Recover To $145 Levels?
Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...
Novo Nordisk: Why The Market Sell-Off On CagriSema Data May Be Justified
Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...
Novo Nordisk to explore CagriSema weight-loss potential in new trial
Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...
GlobalData on MSN9d
Novo Nordisk takes a hit as CagriSema underperforms in weight loss
The Danish company has announced positive results from its Phase III trial of CagriSema but fell short of a previously ...
Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup
Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...
FierceBiotech9d
Novo Nordisk stock crashes after CagriSema misses phase 3 weight-loss goal
A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss ...
Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results
Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...
Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results
Novo traded down more than 20% Friday morning, its biggest loss since 2002. The CagriSema news boosted competitors, such as ...
CagriSema still keeps the Novo Nordisk story in tact, says Barclays' Emily Field
Emily Field, Barclays head of European pharmaceutical research, joins 'Squawk Box' to discuss the state of the weight loss drug market, disappointing trial results of Novo Nordisk's experimental ...